Capgemini-关税成为关键——医疗技术如何大胆抓住时机，打造一个有弹性、数字化驱动的未来（英）

Tariffs as a turning pointHow MedTech can boldly seize the moment and build a resilient, digitally driven future2Tariffs as a turning pointThe fallout is already visible. Stryker1 and Johnson & Johnson2 have projected $200 million and $400 million hits to their MedTech earnings, respectively. If current trends persist, 2026 will bring more challenges. In short, this isn’t a temporary disruption—it marks the start of a multi-year challenge.At the heart of the issue is a business model that hasn’t kept pace with the shift from exclusively hard goods to a digital inclusive mix. Heavy reliance on hardware and hard products means MedTech companies are particularly vulnerable to sourcing and import/export issues like tariffs. When those policies shift on a weekly basis, it is increasingly difficult to manage profit and long-term revenue. It is estimated that nearly 70% of MedTech devices sold in the US are manufactured or have components sourced globally3. Once a strength, complex supply chains now pose a liability in an ever-changing healthcare landscape. At the same time, aging populations and growing pressure within healthcare systems is driving down spending, while events like Covid-19 are increasing expectations around access to healthcare systems and treatments. U.S. tariffs are now squeezing already thin margins, raising material costs, and forcing companies to hold excess inventory, which is driving even further challenges. In 2024, MedTech companies were generally operating between 50–60% gross margins4, though these numbers can vary significantly. Now with tariffs as an additional factor, companies face a choice: Pass rising costs on to the market and exacerbate healthcare affordability or absorb the cost and erode profitability.But there is a third—and more strategic—path: Expanding digital offerings to not only offset tariff costs, but to build a more resilient, profitable, and future-ready business model.Introduction1https://www.medtechdive.com/news/stryker-200m-tariff-hit-earnings-forecast/747011/2https://www.medtechdive.com/news/jnj-tariff-costs-400-million-2025/745357/3https://www.knobbe.com/blog/u-s-tariffs-and-the-medical-device-industry/4https://flgpartners.com/2025-biopharma-medtech-ipo-landscape/In early 2025, the United States introduced sweeping tariffs that have shaken global industries—MedTech included. For a sector dependent on global supply chains and hardware-centric models, the impact has been immediate and severe both for U.S. companies and the global organizations that do business with them. 3Tariffs as a turning pointCountryTop Exported DevicesImport ShareTariff US Imports $BnImpactChinaElectronic components, imaging equipment, diagnostic devices15%54% $2.30 $1.24GermanyOrthopedic devices, dental instruments, surgical tools11%20%$4.46$0.89MexicoSyringes, tubing, electronic subcomponents24%25%$12.00$3.00JapanEndoscopes, diagnostic instruments, imaging systems4%24%$4.00$0.96IrelandImplantable devices, catheters, diagnost